M.Tuberculosis Antigen Test

TB Rapid Antigen Testing — Faster Detection, Closer to Care

Tuberculosis is often considered a low-incidence disease in Europe — yet nearly 40,000 cases are still reported annually across the EU/EEA.
Recent data also show a slowing decline and even short-term increases, highlighting ongoing challenges in early detection.
In many settings, access to timely laboratory diagnostics remains limited, leading to delays or uncertainty in clinical decision-making.

👉 This underlines the need for faster, more accessible diagnostic solutions closer to the point of care.

In practice, TB diagnosis often relies on:

• Centralized laboratory testing (PCR / culture)

• Delayed turnaround times

• Clinical judgement when lab access is limited

This can lead to:

• ❗ Delayed diagnosis

• ❗ Risk of under-diagnosis

• ❗ Risk of over-diagnosis

👉 A gap remains between patient presentation and confirmed diagnosis..

💡 A Complementary Approach: Rapid Antigen Testing

Rapid antigen-based testing offers a practical, decentralized solution to support TB detection — especially where immediate lab access is not available.

Key advantages:

• 📌 Fast results — supports immediate clinical decisions

• 📌 Simple workflow — minimal training required

• 📌 Accessible — suitable for decentralized settings

• 📌 Point-of-care use — closer to the patient

👉 Designed as a complementary tool, not a replacement for molecular testing.

M.Tuberculosis Antigen Rapid Test

The M.Tuberculosis Antigen Rapid Test detects three TB-specific secreted antigens :

ESAT-6, CFP-10, and MPT-64 , which are not present in BCG strains or most non-tuberculosis mycobacteria.